DexCom, Inc. (NASDAQ:DXCM) Stock Position Increased by Oak Harbor Wealth Partners LLC

Oak Harbor Wealth Partners LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 206.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,737 shares of the medical device company’s stock after acquiring an additional 3,862 shares during the quarter. Oak Harbor Wealth Partners LLC’s holdings in DexCom were worth $385,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Capital Insight Partners LLC increased its stake in DexCom by 2.5% in the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares during the period. HM Payson & Co. boosted its holdings in DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after acquiring an additional 100 shares during the period. Clear Creek Financial Management LLC raised its position in shares of DexCom by 4.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after acquiring an additional 120 shares in the last quarter. SeaCrest Wealth Management LLC grew its stake in DexCom by 3.6% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock valued at $501,000 after purchasing an additional 152 shares during the last quarter. Finally, Securian Asset Management Inc. boosted its stake in shares of DexCom by 0.7% in the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock worth $2,593,000 after buying an additional 161 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $74.68 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company’s 50 day moving average is $69.77 and its two-hundred day moving average is $92.14. The firm has a market cap of $29.17 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 2.22 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insider Activity

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on DXCM shares. Sanford C. Bernstein raised their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Wells Fargo & Company upped their target price on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Robert W. Baird lifted their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.